12 juli 2012: hieronder het abstract van onderstaande studie. Ik weet dat John Jacobs afgelopen jaren heel veel meer onderzoek heeft uitgevoerd: op deze website staat al zijn onderzoek

Ook het volledige studierapport van onderstaande studie is tegen betaling in te zien op de website van Nature - Clinical Oncology

Cancer Immunol Immunother. 2005 Aug;54(8):792-8. Epub 2004 Dec 31.

Treatment of stage III-IV nasopharyngeal carcinomas by external beam irradiation and local low doses of IL-2.

Jacobs JJ, Hordijk GJ, Jürgenliemk-Schulz IM, Terhaard CH, Koten JW, Battermann JJ, Den Otter W.

Source

Department of Pathobiology, Utrecht Medical Centre, Yalelaan 1, P.O.Box 80.158, 3508 TD, Utrecht, The Netherlands.

Abstract

The therapeutic effect of intratumoural application of Interleukin-2 (IL-2) was studied in patients with stage III-IV nasopharyngeal carcinoma (NPC) that received radiotherapy. Patients with stage III-IV NPC receiving a standard treatment of 7,000 cGy external beam irradiation have a mean disease-free survival of about 1.5 years. In this paper, we describe ten of these patients who were treated with additional peritumoural and intratumoural injections with 3 x 10(4) U IL-2 on 5 days in weeks 2, 4, and 6 of the 7-weeks' irradiation period. This combined treatment group was compared with a historical group of patients treated with standard irradiation alone. Local IL-2 therapy showed a marked clinical and statistical significant improvement of disease-free survival. After 5 years, 63% of the IL-2 treated patients were disease-free versus 8% of the control patients. These results suggest that the therapeutic results of radiotherapy can be significantly improved by combining it with local IL-2 treatment. To our knowledge, this is the first clinical report showing that local IL-2 therapy is effective against an infiltrative and locally metastasizing tumour in human patients.

PMID:: 15627211; [PubMed - indexed for MEDLINE]

14 november 2005: Bron: Cancerimmunotherapy

Nederlandse onderzoekers in Utrecht hebben een trial met 10 patiënten met neus- en keeltumoren zeer succesvol behandeld met direct injecteren van Interleukin 2. De vijfjaarsoverleving bij deze kleine groep van patiënten, die vaak inoperabel zijn, steeg uiterst spectaculair van 8% bij alleen radiotherapie(bestraling) naar 63% bij het direct injecteren van interleukin 2 in de tumoren in het neus- en keelgebied.

Treatment of advanced nasopharyngeal carcinoma with only radiotherapy has a poor prognosis Nature clinical practices oncology highlights a research paper from Cancer Immunology Immunotherapy. Jacobs and co-workers from Utrecht University, the Netherlands, publish a remarkable improvement of standard radiotherapy. Addition of interleukin 2 injections increases the 5-years disease-free survival from 8% (radiotherapy only) to 63% (combination therapy). Its location makes nasopharyngeal carcinoma difficult to access for surgery. In advanced stages surgery is impossible due to tumour growth in vital parts of the head, like the encephalic trunk. The tumour can be reached with injections containing interleukin 2. Starting 1989, Prof. Den Otter and his group are successful in research of local interleukin 2 therapy of cancer. The activated immune system makes interleukin 2. In animal experiments, diseased animals and human, local interleukin 2 has resulted almost without any side effects, in higher percentage of cures that standard treatment. Local interleukin 2 therapy was successful in experimental animals with different kinds of advanced cancer. Local interleukin 2 has almost no side effects and is much cheaper than radio- or chemotherapy. Its consequence is, unfortunately, that local interleukin 2 is less interesting for pharmaceutical companies. Research with patients was limited to recurrent bladder carcinoma. The current paper adds nasopharyngeal carcinoma to this list A follow-up study with larger number of nasopharyngeal carcinoma patients is planned, in which local interleukin 2 is tested as addition to the newest standard therapy, a combination of radiotherapy and chemotherapy. The research group also intends to do research on patients with other kinds of cancer with a poor prognosis. More information on the research group and their research can be found at this website (www.cancerimmunotherapy.net).

immuuntherapie, keelkanker, mondkanker, neuskanker, interleukin-2